Pulmonary Medicine

Guest: Kathleen M. Buchheit, MD Guest: Joseph K. Han, MD Chronic rhinosinusitis with nasal polyps (CRSwNP) is associated with a low quality of life and increased healthcare utilization, and patients often continue to have severe symptoms despite therapy.​ Understanding the role of underlying inflammatory pathways and epithelial dysfunction may help inform clinical decision making for these patients. In this program, Dr Kathleen Buchheit and Dr Joseph Han share their insights on the pathophysiology of CRSwNP and how unaddressed underlying inflammation may contribute to a variety of challenges for patients. Dr Buchheit is an Assistant Professor of Medicine at Harvard Medical School, specializing in Allergy and Immunology. Dr Han is a Professor of Otolaryngology, the Chief for the Division of Rhinology and Endoscopic Sinus and Skull Base Surgery, and the Chief of the Division of Allergy at Eastern Virginia Medical School in Norfolk, Virginia. References: Mullol J, et al. J Allergy Clin Immunol Pract. 2022;10:1434-1453.e9 LaryngoscopeAllergyJ Allergy Clin Immunol Pract ©2024 Amgen and AstraZeneca. All rights reserved. US-96000 Last Updated 12/24

Guest: Ashwin Basavaraj, MD Guest: Keren Bakal, MD Guest: Nathan Falk, MD, MBA, FAAFP Guest: Amy Springer, NP Often mistaken for COPD or asthma, bronchiectasis and nontuberculous mycobacteria (NTM) can be difficult to recognize and test for, often delaying diagnosis and effective treatment. However, an emphasis on education and research can help address these diagnostic gaps, and involving a multidisciplinary care team can improve treatment plans and patient outcomes. Joining Dr. Ashwin Basavaraj, Associate Professor of Medicine at NYU Grossman School of Medicine, to talk about how we can optimize the diagnosis and management of bronchiectasis and NTM are Dr. Keren Bakal, Dr. Nathan Falk, and Ms. Amy Springer. Dr. Bakal is a pulmonologist specializing in critical care medicine at Overlook Medical Center and Morristown Medical Center in New Jersey, Dr. Falk is a Professor and the founding Residency Director for Family Medicine at Florida State University, and Ms. Springer is a Senior Nurse Practitioner at NYU Langone Health. This program is produced in partnership with the American College of CHEST Physicians, and is sponsored by Insmed Incorporated.

In this brief video, learn more about growing evidence supporting the key role of airway epithelium dysfunction in driving inflammation in CRSwNP. ©2025 Amgen and AstraZeneca. All rights reserved. US-94728 Last Updated 1/25

Host: Isaretta Riley, MD, MPH Guest: Nicola A. Hanania, MD, MS, FCCP Guest: Jay Peters, MD A recent study assessing the impact of implicit bias on uncontrolled asthma treatment found that a patient’s identity and socioeconomic status can unintentionally influence a physician’s decision-making, impacting the quality of care. Additionally, a critical gap exists in clinician awareness and implementation of health equity practices, which play a key role in mitigating these unintended consequences. That’s why Drs. Isaretta Riley, Nicola Hanania, and Jay Peters come together to explore the latest research on unconscious bias in asthma treatment and provide recommendations for more equitable care. Dr. Riley is an Assistant Professor of Medicine at Duke University School of Medicine in Durham, North Carolina; Dr. Hanania is a Professor of Pulmonary Medicine and the Director of Airways Clinical Research Center at Baylor College of Medicine in Houston, Texas; and Dr. Peters is a Professor Emeritus of Medicine in the Division of Pulmonary Diseases and Critical Care Medicine at the University of Texas, San Antonio. This episode of Deep Breaths: Updates from CHEST was supported by a non-promotional, non-CME educational program brought to you by CHEST in collaboration with and sponsored by GSK.

Host: Jacob Sands, MD Guest: Julia Rotow, MD In non-squamous non-small cell lung cancer (NSCLC), a small percentage of patients will have activating HER2 mutations. For these patients, the standard second-line therapy is docetaxel, but this can have poor response rates. That’s why the DESTINY-Lung03 trial examined the safety and efficacy of trastuzumab deruxtecan in patients with pretreated HER2-overexpressing non-squamous NSCLC. Here with Dr. Jacob Sands to share the findings from part 1 of this trial is thoracic medical oncologist Dr. Julia Rotow.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Laura Alder, MD The recent approval of antibody drug conjugates (ADCs) has the potential to address unmet needs associated with second-line treatment options for non-small cell lung cancer, like limited benefits and substantial toxicity. But given the complex structure of ADCs, it’s important to identify biomarkers that can predict a patient’s response to therapy. That’s why the phase 1b TROPION-LUNG02 trial examined the effectiveness of Dato-DXd and HER3-DXd in the presence of predictive biomarkers. Joining Dr. Charles Turck to discuss the trial’s findings and implications is Dr. Laura Alder, Assistant Professor of Medicine at Duke University School of Medicine in Durham, North Carolina.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Thomas Egenod, MD In an effort to identify additional treatment options for resectable non-small cell lung cancer (NSCLC), the NeoCOAST-2 study is evaluating the efficacy and safety of combining durvalumab, chemotherapy, and novel agents in the neoadjuvant setting as well as combining durvalumab with novel agents in the adjuvant setting. Joining Dr. Charles Turck to share the preliminary results regarding the safety, pathological complete response, and major pathological response rates of these two approaches is study investigator Dr. Thomas Egenod, who presented the NeoCOAST-2 study at the 2024 World Conference on Lung Cancer.

Host: Jacob Sands, MD Guest: Alex Spira, MD, PhD, FACP Valemetostat is a novel therapy that’s demonstrated clinical efficacy and safety across multiple hematologic malignancies, but what role might it have in treating patients with advanced, unresectable, or metastatic non-squamous non-small cell lung cancer (NSCLC)? To find out, an upcoming trial is examining the efficacy and safety of combining valemetostat and datopotamab deruxtecan (Dato-DXd). Here with Dr. Jacob Sands to talk about the study’s design and next steps is Dr. Alex Spira, Director of the Thoracic and Phase I Program at Virginia Cancer Specialists Research Institute and a Clinical Assistant Professor at Johns Hopkins.

Host: Jacob Sands, MD Guest: Aaron Lisberg, MD Unfortunately, brain metastases are very common in patients with non-small cell lung cancer (NSCLC). That’s why the phase 3 TROPION-Lung01 trial examined the efficacy and safety of datopotamab deruxtecan (Dato-DXd) for advanced non-squamous NSCLC with brain metastases. Joining Dr. Jacob Sands to share the results presented at the 2024 ESMO Congress is thoracic medical oncologist Dr. Aaron Lisberg.

Host: Jacob Sands, MD Guest: Aaron Lisberg, MD Docetaxel alone or in combination with ramucirumab is the current standard of care for the second-line treatment of non-small cell lung cancer (NSCLC), but there are several limitations of docetaxel-containing regimens. That’s why there’s interest in identifying new therapies like datopotamab deruxtecan (Dato-DXd), which was found to improve overall survival based on an interim analysis. But what are the latest findings? Here to share the final overall survival data on Dato-DXd from the TROPION-Lung01 trial are Drs. Jacob Sands and Aaron Lisberg, who worked together on this research that was presented at the 2024 World Conference on Lung Cancer.

Guest: Vallerie V. McLaughlin, MD Guest: Thomas Cascino, MD Guest: Bradley A. Maron, MD Providers face challenges when it comes to pulmonary hypertension (PH), especially when distinguishing between PAH with comorbidities and group 2 PH. In addition, PH resulting from left heart disease may further complicate diagnosis and treatment. Hear what the experts have to say about identifying and treating these patient populations.

Guest: Robert P. Frantz, MD, FACC Guest: Vallerie V. McLaughlin, MD Guest: Sonja Bartolomei, MD Hear about the latest updates in risk assessment and find out how you can accurately use risk stratification to categorize patients in a timely manner to improve both their care and quality of life. You’ll also discover changing practice trends and the latest evidence that may impact your practice.

Guest: Vallerie V. McLaughlin, MD Guest: Victor Moles, MD Guest: Ioana Preston, MD The landscape of medication management for patients with pulmonary hypertension (PH) has significantly changed with the introduction of combination therapy and recent trial data. This activity presents the latest evidence and breaks down new approaches to the management of PH. Join our experts to find out how your daily practice will be affected.

Guest: Ryan Maves, MD Guest: Susan Corbridge, PhD, APRN, ACNP-BC, FAANP, FCCP, FAAN Although there have been several advances in vaccine technology and safety the past few years, the prevalence of vaccine hesitancy among patients is increasing. Since vaccine hesitancy heightens the burden of potentially life-threatening viruses like RSV and influenza, Dr. Ryan Maves speaks with Dr. Susan Corbridge about why patients might be reluctant to get vaccinated and how we can use the First 5 Minutes approach to provide individualized counseling on the importance of vaccines. Dr. Maves is a Professor of Medicine and Anesthesiology in the Sections of Infectious Diseases and Critical Care Medicine at the Wake Forest University School of Medicine, and Dr. Corbridge is a Professor Emerita at the University of Illinois at Chicago College of Nursing. This episode is supported by an educational grant from Moderna.

Host: Jacob Sands, MD Guest: Marina Garassino, MD Datopotamab deruxtecan (Dato-DXd) is a second-line antibody drug conjugate that could lead to improved progression-free survival in patients with advanced or metastatic non-small cell lung cancer. Given these potential benefits, it’s important to identify biomarkers that may predict a patient’s response to Dato-DXd, which was the focus of recent research presented at the 2024 World Conference on Lung Cancer. Here with Dr. Jacob Sands to discuss a new biomarker for TROP2 is Dr. Marina Garassino, Professor of Medicine and Director of the Thoracic Oncology Program at the University of Chicago.

Host: Angela Birdwell, DO, MA, FCCP Guest: Antonio Anzueto, MD Guest: Susan Corbridge, PhD, APRN, ACNP-BC, FAANP, FCCP, FAAN Although the prevalence of chronic obstructive pulmonary disease (COPD) has decreased in adults aged 18 to 44, it remains elevated in certain patient groups, like women, adults over 65, smokers, and those living in rural areas. This prevalence emphasizes the importance of a patient-centered approach, which is why Dr. Angela Birdwell speaks with Drs. Antonio Anzueto and Susan Corbridge about how open conversations and the First 5 Minutes concept can help personalize the care of COPD patients and lead to better outcomes. Dr. Anzueto is a Professor of Medicine at the South Texas Veterans Health Care System and UT Health San Antonio, and Dr. Corbridge is the Chief Essentials Program Officer at the American Association of Colleges of Nursing and a Professor Emerita at the University of Illinois at Chicago College of Nursing. This non-CME education is brought to you by CHEST, and this program is supported by Regeneron Phamraceuticals, Inc. and Sanofi.

Guest: Surya Bhatt, MD Guest: MeiLan Han, MD, MS Although chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death worldwide, current management does not alter progression of the disease. With the potential for biologically-targeted therapies to be available soon, it is important to address current educational needs related to COPD. This includes knowledge of T2 inflammation in COPD, understanding the clinician’s role in assessing patients for inflammatory types, staying in formed about developing therapies, and adopting strategies that shift COPD management to a more personalized approach.

Guest: Surya Bhatt, MD Guest: MeiLan Han, MD, MS Although chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death worldwide, current management does not alter progression of the disease. With the potential for biologically-targeted therapies to be available soon, it is important to address current educational needs related to COPD. This includes knowledge of T2 inflammation in COPD, understanding the clinician’s role in assessing patients for inflammatory types, staying in formed about developing therapies, and adopting strategies that shift COPD management to a more personalized approach.

Guest: Surya Bhatt, MD Host: MeiLan Han, MD, MS Although chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death worldwide, current management does not alter progression of the disease. With the potential for biologically-targeted therapies to be available soon, it is important to address current educational needs related to COPD. This includes knowledge of T2 inflammation in COPD, understanding the clinician’s role in assessing patients for inflammatory types, staying in formed about developing therapies, and adopting strategies that shift COPD management to a more personalized approach.

Guest: Surya Bhatt, MD Guest: MeiLan Han, MD, MS Although chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death worldwide, current management does not alter progression of the disease. With the potential for biologically-targeted therapies to be available soon, it is important to address current educational needs related to COPD. This includes knowledge of T2 inflammation in COPD, understanding the clinician’s role in assessing patients for inflammatory types, staying in formed about developing therapies, and adopting strategies that shift COPD management to a more personalized approach.